Gastric cancer is a complex disease that often presents with challenging prognoses. HER2+ gastric disease, characterized by the overexpression of the human epidermal growth factor receptor 2, represents a particularly aggressive subtype. Clinical advancements have led to an improved understanding of this disease and the emergence of promising treat